HomeBUSINESS
BUSINESS

AbbVie Hopes Maviret Will Encourage Potential Hep C Patients to Get Treatment: Hepatitis Biz Head
(Dec.11.2017)

Yoshitaka Mizuno, head of hepatitis business unit
AbbVie is working to bring into widespread use the hepatitis C treatment Maviret (glecaprevir + pibrentasvir), which it launched on November 27. The market for hepatitis C treatments has been contracting, but AbbVie plans to promote the product by highlighting its superiority to existing treatments in that it enables eight-week treatment for genotype 1 and 2 hepatitis C, it is a “pan-genotype” drug that also covers other genotypes, which have been hard to treat up to now, and does not require the concurrent administration of ribavirin for genotype 2 ...
(LOG IN FOR FULL STORY)